PD13-14 THE GENETIC INFORMATION OF NON-MUSCLE INVASIVE BLADDER CANCER ASSOCIATED WITH RECURRENCE

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD13-14 THE GENETIC INFORMATION OF NON-MUSCLE INVASIVE BLADDER CANCER ASSOCIATED WITH RECURRENCE Seong Hyeon Yu, Do Gyeong Lim, Jeong Hoon Oh, Jiwon Ryu, Ho Seok Chung, Eu Chang Hwang, Kyung Jin Oh, Sun-Ouck Kim, Seung Il Jung, Taek Won Kang, Kwangsung Park, and Dong Deuk Kwon Seong Hyeon YuSeong Hyeon Yu More articles by this author , Do Gyeong LimDo Gyeong Lim More articles by this author , Jeong Hoon OhJeong Hoon Oh More articles by this author , Jiwon RyuJiwon Ryu More articles by this author , Ho Seok ChungHo Seok Chung More articles by this author , Eu Chang HwangEu Chang Hwang More articles by this author , Kyung Jin OhKyung Jin Oh More articles by this author , Sun-Ouck KimSun-Ouck Kim More articles by this author , Seung Il JungSeung Il Jung More articles by this author , Taek Won KangTaek Won Kang More articles by this author , Kwangsung ParkKwangsung Park More articles by this author , and Dong Deuk KwonDong Deuk Kwon More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003260.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The next-generation sequencing (NGS) is widely used in muscle invasive bladder cancer (MIBC), but limited use in non-muscle invasive bladder cancer (NMIBC) due to significant heterogeneity and high cancer-specific survival. Therefore, we aimed to evaluate the genomic information of NMIBC and identify molecular alteration associated with tumor recurrence. METHODS: A total of 43 patients with NMIBC who underwent transurethral resection of bladder were enrolled. We performed NGS using oncomine panel on tumor specimen and blood sample corresponding to each specimen. The mutation results were analyzed by pairwise comparison according to the recurrence of bladder tumor within 1 year. RESULTS: The median incidence of genetic variation in 43 tumor samples was 53 variations per sample, and high TMB was associated with tumor recurrence. (median variation 33 vs. 64, p=0.023) The most mutated gene was ATM (79%), followed by NF1 (79%), and NOTCH1 (79%). In the results of pairwise comparison according to the recurrence of bladder tumor within 1-year, epidermal growth factor receptor (EGFR) mutation was significant factor associated with tumor recurrence (odds ratio [OR], 4.81; 95% confidence interval [CI], 1.96-32.92, p=0.045). In addition, TERT (OR, 4.10; 95% CI, 0.92-22.38, p=0.054) and MYCL (OR, 5.22; 95% CI, 0.86-57.88, p=0.068) might be the associated factor of tumor recurrence. CONCLUSIONS: Our results revealed that EGFR mutation has a prognostic value on tumor recurrence of NMIBC; therefore, EGFR might be a useful prognostic biomarker in NMIBC. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e411 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Seong Hyeon Yu More articles by this author Do Gyeong Lim More articles by this author Jeong Hoon Oh More articles by this author Jiwon Ryu More articles by this author Ho Seok Chung More articles by this author Eu Chang Hwang More articles by this author Kyung Jin Oh More articles by this author Sun-Ouck Kim More articles by this author Seung Il Jung More articles by this author Taek Won Kang More articles by this author Kwangsung Park More articles by this author Dong Deuk Kwon More articles by this author Expand All Advertisement PDF downloadLoading ...